SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
From: nigel bates7/18/2007 8:14:14 AM
   of 625
 
The following is a summary of Abbott's second-quarter 2007 sales for
selected products.


    Quarter Ended 6/30/07             Percent         Percent          Percent
    (dollars in millions)              Change   Rest   Change           Change
                               U.S.      vs.     of      vs.    Global   vs.
                              Sales     2Q06    World   2Q06    Sales   2Q06
    Pharmaceutical Products
    HUMIRA                     $406     43.7    $329    58.0 (a) $735    49.8
    Depakote                   $382     27.9     $22    11.5     $404    26.9
    Kaletra                    $132     11.7    $183    24.7 (b) $315    18.9
    TriCor                     $302     20.6     ---     ---     $302    20.6
    Ultane/Sevorane             $53    (18.5)   $144     0.9 (c) $197    (5.1)
    Biaxin (clarithromycin)      $4    (85.3)   $166     0.4 (d) $170   (12.4)
    Niaspan                    $170      n/a     ---     ---     $170     n/a
    Synthroid                  $103     (8.2)    $18    12.7     $121    (5.6)


...Abbott recently raised its global sales forecast for HUMIRA to more than $2.8 billion in 2007...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News